{"name": "Novelos Therapeutics",
 "permalink": "novelos-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/novelos-therapeutics",
 "homepage_url": "http://www.novelos.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "608-441-8120",
 "description": "",
 "created_at": "Tue Apr 12 03:44:25 UTC 2011",
 "updated_at": "Fri Jun 15 01:24:50 UTC 2012",
 "overview": "\u003Cp\u003ENovelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company\u00e2\u20ac\u2122s compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company\u00e2\u20ac\u2122s second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       30],
      "assets/images/resized/0013/0139/130139v1-max-150x150.png"],
     [[162,
       33],
      "assets/images/resized/0013/0139/130139v1-max-250x250.png"],
     [[162,
       33],
      "assets/images/resized/0013/0139/130139v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Harry",
      "last_name": "S. Palmin",
      "permalink": "harry-s-palmin",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$5.1M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.novelos.com/docs/Novelos%20PR%204-11-11%20acquisition-financing.pdf",
    "source_description": "NOVELOS THERAPEUTICS COMPLETES ACQUISITION AND $5.1 MILLION FINANCING TO DEVELOP 3 NOVEL CANCER-TARGETED COMPOUNDS",
    "raised_amount": 5100000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 11,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": null,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.novelos.com/docs/Novelos%20PR%204-11-11%20acquisition-financing.pdf",
    "source_description": "NOVELOS THERAPEUTICS COMPLETES ACQUISITION AND $5.1 MILLION FINANCING TO DEVELOP 3 NOVEL CANCER-TARGETED COMPOUNDS",
    "acquired_year": 2011,
    "acquired_month": 4,
    "acquired_day": 11,
    "company":
     {"name": "Cellectar",
      "permalink": "cellectar",
      "image": null}}],
 "offices":
  [{"description": "",
    "address1": "3301 Agriculture Drive",
    "address2": "",
    "zip_code": "53716",
    "city": "Madison",
    "state_code": "WI",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Novelos closes $5M offering; fraud complaint dismissed",
    "stoned_year": 2012,
    "stoned_month": 6,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2012/06/11/daily39-Novelos-closes-5M-offering-fraud-complaint-dismissed.html",
    "source_text": "",
    "source_description": "Novelos closes $5M offering; fraud complaint dismissed",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Novelos Therapeutics",
      "permalink": "novelos-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}